查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1461244

全球加巴喷丁市场：依剂型、应用、给药途径、购买模式、分销管道和地区划分的机会和预测（2017-2031）

Gabapentin Market Assessment, By Dosage Form, By Application, By Route of Administration, By Mode of Purchase,, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 232 Pages | 商品交期: 3-5个工作天内

价格
根据预测，全球加巴喷丁市场规模将从2023年的25.1亿美元成长到2031年的37.7亿美元，2024-2031年预测期间复合年增长率为5.2%。 市场需求是由製药公司增加对产品创新活动的投资、各监管机构增加产品批准以及扣押事件数量的增加所推动的。

不断增长的老年人口也将加强对全球加巴喷丁市场的需求，因为老年人口更容易受到需要加巴喷丁的各种健康状况的影响，例如不宁腿综合征、神经性疼痛和癫痫，这是主要因素。 因此，这些疾病在老年人口中的盛行率不断增加，增加了对加巴喷丁的需求，从而加强了市场收入的成长。

此外，由于世界各地癫痫病例数量不断增加，医疗保健部门越来越多地使用加巴喷丁。 例如，根据世界卫生组织(WHO)称，癫痫是最常见的神经系统疾病之一，全球约有5,000万人患有癫痫。 癫痫的可能原因包括中风、肿瘤、神经传导物质失衡、神经传递化学物质和损伤引起的脑损伤。 由于这些因素，癫痫病例数量显着增加，需要加巴喷丁来有效治疗癫痫。

本报告调查了全球加巴喷丁市场，并提供了市场概况，以及依剂型、应用、给药途径、购买形式、分销管道、地区和进入市场的公司的趋势。

目录

第一章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第 4 章顾客回馈

第五章2017-2031 年全球加巴喷丁市场展望

  • 市场规模与预测
  • 依剂型
  • 依用途
  • 依给药途径
  • 依购买类型
  • 依分销管道
  • 依地区
  • 各公司的市占率 (%)，2023 年

第 6 章 2017-2031 年全球加巴喷丁市场展望（依地区）

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第七章供给面分析

第 8 章 2023 年市场规划

  • 依剂型
  • 依用途
  • 依给药途径
  • 依购买类型
  • 依分销管道
  • 依地区

第九章宏观环境与产业结构

  • 供应需求分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 10 章市场动态

第十一章 主要与会企业状况

第十二章价格分析

第 13 章案例研究

第 14 章主要进入者展望

  • Pfizer, Inc.
  • Zydus Cadila Healthcare Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Cipla USA, Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Ascend Laboratories, LLC
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.

第 15 章策略建议

第十六章查询及免责声明

Product Code: MX11245

Global gabapentin market is projected to witness a CAGR of 5.2% during the forecast period 2024-2031, growing from USD 2.51 billion in 2023 to USD 3.77 billion in 2031F. The market demand is boosted by increasing investments in product innovation activities by pharmaceutical companies, growing provision of product approvals by different regulatory bodies, and rising incidences of seizures.

Pharma companies are actively investing in research and development. For instance, in 2023, Swiss healthcare companies Novartis and Roche ramped up their research and development spending by 6%, with Novartis investing approximately USD 12.1 billion in investments in neuroscience and oncology and Roche investing USD 12.1 billion. Merck & Co. were noted to have the highest R&D ratio of 51%, followed by Novartis and Roche, at 30% each. Such investments aid in the development of novel products and in determining the alternate uses of existing products, which in turn is accelerating the gabapentin market growth.

The expansion of the geriatric population is another major factor bolstering the global gabapentin market demand as they are more susceptible to various health conditions, such as restless legs syndrome, neuropathic pain, epilepsy, and others, that require gabapentin. Thus, due to the growing prevalence of these conditions in the geriatric population, the demand for gabapentin is increasing, thereby bolstering the market's revenue growth.

Additionally, the increasing deployment of gabapentin by the healthcare sector is attributed to the increasing cases of epilepsy in various regions across the globe. For instance, according to the World Health Organization (WHO), epilepsy is one of the most common neurological conditions, with approximately 50 million individuals suffering from it across the globe. The different possible causes of epilepsy include strokes, tumors, imbalance of neurotransmitters, nerve-signaling chemicals, and brain damage caused by injury. Thus, due to these factors, the number of cases of epilepsy is significantly rising, propelling the requirement for gabapentin for effective management of the condition, thereby providing lucrative growth opportunities to the market.

Moreover, the Global Medicine Spending and Usage Trends: Outlook to 2025 report suggests that the medicines market is expected to grow at a CAGR of 3-6% by 2025, reaching approximately USD 1.6 trillion. Thus, the pharmaceutical market will offer lucrative growth opportunities to the global gabapentin market over the coming years.

Prevalence of Neuropathic Pain is Accelerating Market Expansion

The increasing prevalence of neuropathic pain due to damage to nerves, alcoholism, multiple sclerosis, spine injury, diabetes, thyroid disease, and others is one of the major factors boosting the global gabapentin market size. For instance, in 2021, the IDF Diabetes Atlas reported that 10.5% of the individuals from age group 20-79 years are living with diabetes. They project that by 2045, one out of eight adults (about 783 million) will suffer from diabetes. Hence, the increase in the cases of diabetes is propelling the requirement for gabapentin as over long durations of time; uncontrolled high blood sugar might cause damage to nerves, interfering with their ability to send signals, and causing diabetic neuropathy.

Meanwhile, the expansion of the geriatric population is bolstering the product requirement. For instance, according to an article published on PAIN Reports in March 2023, estimates of neuropathic pain in the general population indicate a prevalence of 7-10%. The number increases to approximately 20-30% in individuals with diabetes. Earlier studies have indicated a higher prevenance of neuropathic pain in older populations. Hence, due to it the demand for gabapentin is increasing for effective management of neuropathic pain in this population, which is propelling the expansion of the market.

Government Initiatives to Boost Awareness of Non-Communicable Chronic Conditions Aids Global Gabapentin Market Growth

The growing initiatives by various governments across the globe to increase awareness about epilepsy, among other non-communicable chronic conditions and the available treatments, are augmenting the market expansion. For instance, according to the estimates of the World Health Organization (WHO), approximately five million individuals around the world are diagnosed with epilepsy every year, propelling the requirement for medication to treat epilepsy, including gabapentin. To support this condition, the 75th WHA adopted the Intersectoral global action plan on epilepsy and other neurological disorders 2022-2031. They recognize the shared psychosocial and pharmacological approaches between epilepsy and other neurological disorders, serving as entry points to strengthen the support provided for these conditions. Therefore, due to the implementation of such initiatives, the awareness about epilepsy and the available treatment solutions is increasing; this, in turn, is propelling the requirement for gabapentin and positively influencing the growth of the market.

North America is Anticipated to Account for a Significant Market Share

The presence of a well-established healthcare sector, easy availability and adoption of technologically advanced solutions, and accessibility to health insurance are some of the major factors supporting the growth of North America gabapentin market. The surging provision of approvals by different regulatory bodies, such as the United States Food and Drug Administration (USFDA), coupled with increasing initiatives by pharmaceutical companies and governments to enhance awareness about neurological conditions and their treatments, further support the market growth.

For instance, in March 2024, Strides Pharma Science Limited received approval by the USFDA for gabapentin tablets USP in 800mg and 600mg. The approval is expected to enhance Stride's product portfolio and help it cater to the requirements of individuals suffering from neurological conditions. The approval complements the company's existing approvals that hold a market size of USD 208 million.

Additionally, various pharma players and product manufacturers headquartered in the region are heavily investing in research and development activities to support the development of novel medications, further providing lucrative growth opportunities to the market in North America.

For instance, in 2023 Pfizer generated revenue of approximately USD 58 billion and invested around USD 10 billion in research and development, capping the R&D ratio at 18%. Henceforth, such increased investments are expected to support innovations and different methodological processes that aim to develop and introduce various medications into the market, bolstering the global gabapentin market expansion.

Increasing Incidences of Epilepsy Boosts the Market Growth

Epilepsy is a disorder of the brain that is caused by brain tumors, infection in the central nervous system, stroke, and traumatic brain injury. The oral dosage of gabapentin for epilepsy, for adults includes three doses a day of 300 mg, depending upon the recommendation of the physician. However, the dose should not exceed more than 1800 mg per day. For children aged 3-11, the dose is determined by the doctor depending upon the body weight and is initially approximately 10-15 mg per kilogram and is adjusted into three doses per day.

For instance, according to the estimates of the Centers for Disease Control and Prevention, approximately 1.2% of the population of the United States suffer from active epilepsy. The condition affects approximately 470,000 children and 3 million adults in the country. It, in turn is augments the requirement for gabapentin for preventing seizures by supporting the reduction of abnormal electrical activity in brain. Thus, the rising awareness about the condition and increased acceptance of different therapeutic solutions including gabapentin is expected to offer lucrative growth opportunities to the market.

Hospital Pharmacies are Expected to Account for Significant Global Gabapentin Market Share

The segment expansion can be attributed to increasing integration of electronic prescription systems by hospital pharmacies. These systems enhance patient satisfaction and compliance by aiding in streamlining the practice workflow and reducing the number of callbacks from pharmacies to physicians, boosting customer convenience. Due to these benefits the segment is witnessing rapid growth.

For instance, Apollo Hospital's pharmacy business is expected to touch USD 1.2 billion (INR 10,000 crore) revenue by the end of 2024. The rise can be attributed to the consumer preference for purchasing medication for managing chronic health conditions such as epilepsy from reputed hospital pharmacies because of pre-established trust and the presence of helpful pharmacists. Henceforth, such expansions will ensure accessibility to anti-epileptic medications, including gabapentin, supporting the market's growth.

Future Market Scenario (2024 - 2031F)

According to the global gabapentin market analysis, the increase in cases of restless leg syndrome, neuropathic pain, and epilepsy over the coming years will augment the requirement for gabapentin for treating and managing these conditions, thereby bolstering the market expansion.

The rising conduction of clinical trials for determining the doses of antiepileptic drugs, including gabapentin required for treating different epileptic conditions and augmenting investments towards research and development activities for identifying the alternative applications of gabapentin are expected to offer lucrative growth opportunities to the market over the forecast period.

The ongoing development of new healthcare facilities will boost the supply of gabapentin across various regions, thereby creating a favorable growth potential for the growth of the market in the long run.

Key Players Landscape and Outlook

Various leading market players are investing heavily in research and development activities to strengthen their position in the market. These activities allow them to develop new products, evaluate the working and functioning of existing products for different applications, and assess the safety and efficacy of both existing and novel products. This allows the company to send more products for approval to different regulatory bodies such as the United States Food and Drug Administration (USFDA).

For instance, in January 2024, Zydus Lifesciences Limited secured approval for marketing and manufacturing Gabapentin tablets by the United States Food and Drug Administration. The product is primarily used for the management of Postherpetic Neuralgia, a condition known for causing lasting pain in the skin areas affected by shingles. The approval adds to the company's 448 filed Abbreviated New Drug Applications (ANDAs) and 384 approvals. Such approvals allow market players to expand their customer base, supporting the market expansion.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Voice of Customer

  • 4.1.Market Awareness and Product Information
  • 4.2.Brand Awareness and Loyalty
  • 4.3.Factors Considered in Purchase Decision
    • 4.3.1.Brand Name
    • 4.3.2.Quality
    • 4.3.3.Quantity
    • 4.3.4.Price
    • 4.3.5.Product Specification
    • 4.3.6.Form Specification
    • 4.3.7.Shelf Life
    • 4.3.8.Availability of Product
  • 4.4.Frequency of Purchase
  • 4.5.Medium of Purchase

5.Global Gabapentin Market Outlook, 2017-2031F

  • 5.1.Market Size & Forecast
    • 5.1.1.By Value
    • 5.1.2.By Volume
  • 5.2.By Dosage Form
    • 5.2.1.Oral Solution
    • 5.2.2.Tablet
    • 5.2.3.Capsule
  • 5.3.By Application
    • 5.3.1.Restless Legs Syndrome
    • 5.3.2.Neuropathic Pain
    • 5.3.3.Epilepsy
    • 5.3.4.Others
  • 5.4.By Route of Administration
    • 5.4.1.Intravenous
    • 5.4.2.Oral
    • 5.4.3.Parenteral
  • 5.5.By Mode of Purchase
    • 5.5.1.Over-the-Counter
    • 5.5.2.Prescription
    • 5.5.3.Retail
  • 5.6.By Distribution Channel
    • 5.6.1.Retail Pharmacy
    • 5.6.2.Hospital Pharmacy
    • 5.6.3.Online Pharmacy
    • 5.6.4.Others
  • 5.7.By Region
    • 5.7.1.North America
    • 5.7.2.South America
    • 5.7.3.Europe
    • 5.7.4.Asia-Pacific
    • 5.7.5.Middle East & Africa
  • 5.8.By Company Market Share (%), 2023

6.Global Gabapentin Market Outlook, By Region, 2017-2031F

  • 6.1.North America*
    • 6.1.1.Market Size & Forecast
      • 6.1.1.1.By Value
      • 6.1.1.2.By Volume
    • 6.1.2.By Dosage Form
      • 6.1.2.1.Oral Solution
      • 6.1.2.2.Tablet
      • 6.1.2.3.Capsule
    • 6.1.3.By Application
      • 6.1.3.1.Restless Legs Syndrome
      • 6.1.3.2.Neuropathic Pain
      • 6.1.3.3.Epilepsy
      • 6.1.3.4.Others
    • 6.1.4.By Route of Administration
      • 6.1.4.1.Intravenous
      • 6.1.4.2.Oral
      • 6.1.4.3.Parenteral
    • 6.1.5.By Mode of Purchase
      • 6.1.5.1.Over-the-Counter
      • 6.1.5.2.Prescription
      • 6.1.5.3.Retail
    • 6.1.6.By Distribution Channel
      • 6.1.6.1.Retail Pharmacy
      • 6.1.6.2.Hospital Pharmacy
      • 6.1.6.3.Online Pharmacy
      • 6.1.6.4.Others
    • 6.1.7.United States*
      • 6.1.7.1.Market Size & Forecast
      • 6.1.7.1.1.By Value
      • 6.1.7.1.2.By Volume
      • 6.1.7.2.By Dosage Form
      • 6.1.7.2.1.Oral Solution
      • 6.1.7.2.2.Tablet
      • 6.1.7.2.3.Capsule
      • 6.1.7.3.By Application
      • 6.1.7.3.1.Restless Legs Syndrome
      • 6.1.7.3.2.Neuropathic Pain
      • 6.1.7.3.3.Epilepsy
      • 6.1.7.3.4.Others
      • 6.1.7.4.By Route of Administration
      • 6.1.7.4.1.Intravenous
      • 6.1.7.4.2.Oral
      • 6.1.7.4.3.Parenteral
      • 6.1.7.5.By Mode of Purchase
      • 6.1.7.5.1.Over-the-Counter
      • 6.1.7.5.2.Prescription
      • 6.1.7.5.3.Retail
      • 6.1.7.6.By Distribution Channel
      • 6.1.7.6.1.Retail Pharmacy
      • 6.1.7.6.2.Hospital Pharmacy
      • 6.1.7.6.3.Online Pharmacy
      • 6.1.7.6.4.Others
    • 6.1.8.Canada
    • 6.1.9.Mexico

All segments will be provided for all regions and countries covered

  • 6.2.Europe
    • 6.2.1.Germany
    • 6.2.2.France
    • 6.2.3.Italy
    • 6.2.4.United Kingdom
    • 6.2.5.Russia
    • 6.2.6.Netherlands
    • 6.2.7.Spain
    • 6.2.8.Turkey
    • 6.2.9.Poland
  • 6.3.Asia-Pacific
    • 6.3.1.India
    • 6.3.2.China
    • 6.3.3.Japan
    • 6.3.4.Australia
    • 6.3.5.Vietnam
    • 6.3.6.South Korea
    • 6.3.7.Indonesia
    • 6.3.8.Philippines
  • 6.4.South America
    • 6.4.1.Brazil
    • 6.4.2.Argentina
  • 6.5.Middle East & Africa
    • 6.5.1.Saudi Arabia
    • 6.5.2.UAE
    • 6.5.3.South Africa

7.Supply Side Analysis

  • 7.1.Capacity, By Company
  • 7.2.Production, By Company
  • 7.3.Operating Efficiency, By Company
  • 7.4.Key Plant Locations (Up to 25)

8.Market Mapping, 2023

  • 8.1.By Dosage Form
  • 8.2.By Application
  • 8.3.By Route of Administration
  • 8.4.By Mode of Purchase
  • 8.5.By Distribution Channel
  • 8.6.By Region

9.Macro Environment and Industry Structure

  • 9.1.Supply Demand Analysis
  • 9.2.Import Export Analysis
  • 9.3.Value Chain Analysis
  • 9.4.PESTEL Analysis
    • 9.4.1.Political Factors
    • 9.4.2.Economic System
    • 9.4.3.Social Implications
    • 9.4.4.Technological Advancements
    • 9.4.5.Environmental Impacts
    • 9.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 9.5.Porter's Five Forces Analysis
    • 9.5.1.Supplier Power
    • 9.5.2.Buyer Power
    • 9.5.3.Substitution Threat
    • 9.5.4.Threat from New Entrant
    • 9.5.5.Competitive Rivalry

10.Market Dynamics

  • 10.1.Growth Drivers
  • 10.2.Growth Inhibitors (Challenges and Restraints)

11.Key Players Landscape

  • 11.1.Competition Matrix of Top Five Market Leaders
  • 11.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 11.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4.SWOT Analysis (For Five Market Players)
  • 11.5.Patent Analysis (If Applicable)

12.Pricing Analysis

13.Case Studies

14.Key Players Outlook

  • 14.1.Pfizer, Inc.
    • 14.1.1.Company Details
    • 14.1.2.Key Management Personnel
    • 14.1.3.Products & Services
    • 14.1.4.Financials (As reported)
    • 14.1.5.Key Market Focus & Geographical Presence
    • 14.1.6.Recent Developments
  • 14.2.Zydus Cadila Healthcare Ltd.
  • 14.3.Glenmark Pharmaceuticals Ltd.
  • 14.4.Cipla USA, Inc.
  • 14.5.Novartis AG
  • 14.6.Sun Pharmaceutical Industries Ltd.
  • 14.7.Teva Pharmaceutical Industries Ltd.
  • 14.8.Ascend Laboratories, LLC
  • 14.9.Amneal Pharmaceuticals, Inc.
  • 14.10.Apotex Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

15.Strategic Recommendations

16.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 3.Global Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 4.Global Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 5.Global Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6.Global Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 7.Global Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 8.Global Gabapentin Market Share (%), By Region, 2017-2031F
  • Figure 9.North America Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 10.North America Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 11.North America Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 12.North America Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 13.North America Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 14.North America Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 15.North America Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 16.North America Gabapentin Market Share (%), By Country, 2017-2031F
  • Figure 17.United States Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 18.United States Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 19.United States Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 20.United States Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 21.United States Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22.United States Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 23.United States Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 24.Canada Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 25.Canada Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 26.Canada Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 27.Canada Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 28.Canada Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 29.Canada Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 30.Canada Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 31.Mexico Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 32.Mexico Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 33.Mexico Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 34.Mexico Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 35.Mexico Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 36.Mexico Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 37.Mexico Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 38.Europe Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 39.Europe Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 40.Europe Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 41.Europe Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 42.Europe Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43.Europe Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 44.Europe Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 45.Europe Gabapentin Market Share (%), By Country, 2017-2031F
  • Figure 46.Germany Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.Germany Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 48.Germany Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 49.Germany Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 50.Germany Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 51.Germany Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 52.Germany Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 53.France Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 54.France Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 55.France Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 56.France Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 57.France Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58.France Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 59.France Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 60.Italy Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 61.Italy Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 62.Italy Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 63.Italy Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 64.Italy Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 65.Italy Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 66.Italy Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 67.United Kingdom Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 68.United Kingdom Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 69.United Kingdom Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 70.United Kingdom Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 71.United Kingdom Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 72.United Kingdom Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 73.United Kingdom Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 74.Russia Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 75.Russia Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 76.Russia Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 77.Russia Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 78.Russia Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 79.Russia Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 80.Russia Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 81.Netherlands Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 82.Netherlands Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 83.Netherlands Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 84.Netherlands Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 85.Netherlands Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 86.Netherlands Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 87.Netherlands Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88.Spain Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Spain Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 90.Spain Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 91.Spain Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 92.Spain Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 93.Spain Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 94.Spain Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 95.Turkey Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 96.Turkey Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 97.Turkey Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 98.Turkey Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 99.Turkey Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 100.Turkey Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 101.Turkey Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 102.Poland Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 103.Poland Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 104.Poland Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 105.Poland Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 106.Poland Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 107.Poland Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 108.Poland Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 109.South America Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 110.South America Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 111.South America Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 112.South America Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 113.South America Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 114.South America Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 115.South America Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116.South America Gabapentin Market Share (%), By Country, 2017-2031F
  • Figure 117.Brazil Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 118.Brazil Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 119.Brazil Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 120.Brazil Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 121.Brazil Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 122.Brazil Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 123.Brazil Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 124.Argentina Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 125.Argentina Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 126.Argentina Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 127.Argentina Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 128.Argentina Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 129.Argentina Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 130.Argentina Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131.Asia-Pacific Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 132.Asia-Pacific Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 133.Asia-Pacific Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 134.Asia-Pacific Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 135.Asia-Pacific Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 136.Asia-Pacific Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 137.Asia- Pacific Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138.Asia-Pacific Gabapentin Market Share (%), By Country, 2017-2031F
  • Figure 139.India Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 140.India Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 141.India Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 142.India Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 143.India Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 144.India Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 145.India Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 146.China Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 147.China Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 148.China Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 149.China Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 150.China Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 151.China Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 152.China Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 153.Japan Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 154.Japan Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 155.Japan Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 156.Japan Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 157.Japan Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 158.Japan Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 159.Japan Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 160.Australia Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 161.Australia Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 162.Australia Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 163.Australia Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 164.Australia Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 165.Australia Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 166.Australia Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 167.Vietnam Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 168.Vietnam Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 169.Vietnam Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 170.Vietnam Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 171.Vietnam Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 172.Vietnam Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 173.Vietnam Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174.South Korea Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 175.South Korea Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 176.South Korea Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 177.South Korea Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 178.South Korea Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 179.South Korea Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 180.South Korea Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181.Indonesia Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.Indonesia Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 183.Indonesia Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 184.Indonesia Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 185.Indonesia Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 186.Indonesia Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 187.Indonesia Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 188.Philippines Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 189.Philippines Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 190.Philippines Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 191.Philippines Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 192.Philippines Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 193.Philippines Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 194.Philippines Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 195.Middle East & Africa Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 196.Middle East & Africa Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 197.Middle East & Africa Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 198.Middle East & Africa Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 199.Middle East & Africa Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 200.Middle East & Africa Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 201.Middle East & Africa Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 202.Middle East & Africa Gabapentin Market Share (%), By Country, 2017-2031F
  • Figure 203.Saudi Arabia Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 204.Saudi Arabia Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 205.Saudi Arabia Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 206.Saudi Arabia Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 207.Saudi Arabia Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 208.Saudi Arabia Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 209.Saudi Arabia Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 210.UAE Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 211.UAE Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 212.UAE Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 213.UAE Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 214.UAE Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 215.UAE Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 216.UAE Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 217.South Africa Gabapentin Market, By Value, In USD Billion, 2017-2031F
  • Figure 218.South Africa Gabapentin Market, By Volume, In Kilotons, 2017-2031F
  • Figure 219.South Africa Gabapentin Market Share (%), By Dosage Form, 2017-2031F
  • Figure 220.South Africa Gabapentin Market Share (%), By Application, 2017-2031F
  • Figure 221.South Africa Gabapentin Market Share (%), By Route of Administration, 2017-2031F
  • Figure 222.South Africa Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
  • Figure 223.South Africa Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 224.By Dosage Form Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225.By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227.By Mode of Purchase Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228.By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023